Repatha (evolocumab)

pCPA File Number: 22524

Negotiation Status:

Active Negotiation

Indication(s):

Reduction of elevated LDL-C in adult patients with heterozygous familial hypercholesterolemia (HeFH).

Sponsor/Manufacturer:

Amgen Canada Inc.

CADTH Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2023-11-01

Negotiation Process Concluded:

Not Applicable